This clinical trial tests cold cap therapy for the prevention of hair loss in pediatric and young adult patients undergoing chemotherapy for non-malignant and malignant solid tumors. The chemotherapy that patients are given is known to cause people’s hair to fall out. Cold cap therapy using the Paxman scalp cooling device may help prevent or lessen hair loss in these patients.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04764357.
PRIMARY OBJECTIVE:
I. To assess the safety and feasibility of the use of a scalp cooling device in pediatric and young adult patients receiving chemotherapy for non-malignant conditions and solid tumors.
EXPLORATORY OBJECTIVE:
I. To assess the incidence and intensity of chemotherapy induced hair loss in patients receiving chemotherapy for non-malignant conditions and solid tumors who have used a scalp cooling device.
OUTLINE:
Patients receive cold cap therapy as delivered by the Paxman scalp cooling system 30-45 minutes prior to each chemotherapy administration, throughout administration, and up to 120-180 minutes after discontinuing administration.
Following completion of study intervention, patients with non-malignant disease are followed up at 4 weeks after last dose of chemotherapy and for patients with malignant disease at 4 weeks after last dose of chemotherapy, every 3 months for the first year, and then every year for 5 years.
Trial PhaseNo phase specified
Trial Typedevice
Lead OrganizationSaint Jude Children's Research Hospital
Principal InvestigatorDeena Rachel Levine